Introduction
============

Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory systemic disorders primarily targeting skeletal muscles with or without skin involvement. Several recent reports have demonstrated obvious differences in flow cytometry of circulating peripheral blood and immunohistochemistry of skeletal muscles between PM and DM,[@b1-cmamd-5-2012-043]--[@b3-cmamd-5-2012-043] but both disorders are similar with regard to showing an important role of activated T-lymphocytes in the pathogenesis.[@b4-cmamd-5-2012-043] To control the disease activity of PM and DM via suppression of activated T-lymphocytes, calcineurin inhibitors, such as cyclosporin A (CyA) and tacrolimus, have recently been used for treatment of refractory cases unresponsive to corticosteroid alone, particularly in patients with progressive interstitial pneumonia (IP) in which many CD8-positive cells are frequently detectable in both the alveolar wall and bronchoalveolar fluid.[@b5-cmamd-5-2012-043]--[@b7-cmamd-5-2012-043] Additional use of calcineurin inhibitors in these cases may be able to promote early recovery, save life and also reduce corticosteroid-induced adverse events.[@b1-cmamd-5-2012-043],[@b8-cmamd-5-2012-043]--[@b11-cmamd-5-2012-043]

In the present study we retrospectively investigated the clinical outcomes of prednisolone (PSL) and CyA in acute IP complicating PM/DM in order to clarify therapeutic efficacy and adverse effects. We postulate that additional use of CyA to corticosteroid, particularly continuous intravenous administration of the former in the early phase of illness, may be a potent therapeutic option for PM/DM patients associated with IP probably showing a poor prognosis.

Patients and Methods
====================

Patients
--------

We studied 9 patients with PM (8 women and 1 man; mean age 65 ± 15 years, range 28 to 81) and 33 patients with DM (20 women and 13 men; mean age 52 ± 17 years, range 15 to 83) who had been admitted to our hospital from January 2002 to August 2010. The diagnoses of PM and DM were made according to the classification criteria proposed by Bohan and Peter.[@b12-cmamd-5-2012-043] None of the patients had received any treatment prior to admission to our hospital, and presented with some of the clinical manifestations and laboratory data suggestive of active disease, such as muscle weakness, skin symptoms and increases in serum creatine kinase (CK). Sixteen of the DM patients were compatible with clinically amyopathic DM (CADM) with regard to showing typical skin symptoms, including heliotrope rash, Gottron's sign and ulcerations, with no or little muscle involvement.[@b13-cmamd-5-2012-043] No patients had either malignancy on intensive systemic survey or obvious renal dysfunction on routine laboratory examinations. Other clinical information, such as C-reactive protein (CRP) and autoantibodies, was obtained from their medical records. The Local Ethical Committee approved this study.

Clinical assessment of IP
-------------------------

We assessed pulmonary involvement in the patients using the following indices: chest X-ray, high resolution computed tomography (HRCT), arterial oxygen pressure (PaO~2~) in room air, serum KL-6 and respiratory function tests, including a percent vital capacity (%VC) and a percent diffusing capacity for carbon monoxide (%DLco). HRCT was performed using LightSpeed VCT VISION (GE Healthcare Japan; Hino, Japan), with 2-mm collimation at 15-mm intervals at end inspiration from the lung apices to the bases. All images were reconstructed with a high-spatial frequency algorithm, and photographed at window widths of −1500 H.U. and window levels of −600 H.U. To discover interstitial changes in lungs, we focus upon the following CT findings:[@b14-cmamd-5-2012-043],[@b15-cmamd-5-2012-043] (1) nodular opacities: (2) bronchial dilatation and wall thickening, including consolidation around bronchovascular bundles: (3) reticular opacities, including honey-comb changes: (5) linear opacities and (6) increased lung opacities. When the patients with at least one of these CT findings showed clinical symptoms, such as non-productive cough and exertional dyspnea, with impaired respiratory function, particularly decreases in PaO~2~ (\<80 mmHg),%VC (\<80%) and/or % DLco (\<70%), associated IP was regarded as active. To assess IP, we selected 6 transverse CT images taken at the levels of the upper and lower portions each of the aortic arch, the hilus and the lower lobe. Two raters blinded to the clinical information (YS and MM) evaluated the HRCT images focusing the above-mentioned 6 CT findings suggestive of IP, and used the visual estimation method described by Kinoshita et al.[@b14-cmamd-5-2012-043] Each CT slice level was divided into 4 areas according to a horizontal and a vertical line drawn by a rater, and scored in a semiquatitative manner as follows: 0 = absent; 1 = less than 25% involved; 2 = 25%--50% involved; 3 = 50%--75% involved; and 4 = greater than 75% involved. The final judgment was reached by consensus of the 2 raters. Right and left lungs were evaluated separately, and the sum was expressed as the total CT score. HRCT was serially performed before and after treatment.

Treatment
---------

PSL was started at a dose of approximately 1.0 mg/kg/day in all of the patients soon after the diagnosis of PM/DM. We added CyA to PSL when active IP was evident (PSL + CyA). CyA was orally given twice a day initially at a dose of 75 mg, which was later controlled to keep the trough concentration between 100 and 150 ng/mL. Continuous intravenous administration of CyA was performed when oral intake of it was difficult because of critical care for respiratory failure, such as oxygen therapy with or without mechanical ventilatory support. CyA was started at 0.17 mg/kg/hr, the blood concentration was checked at least twice a day, and in order to keep it at 250--350 ng/mL the administration speed of CyA was controlled. The dose of CyA was reduced at the development of renal dysfunction.

Statistics
----------

To determine statistical differences between PSL alone and PSL + CyA in PM/DM and also those between recovery and death groups in DM, Mann-Whitney's U and Chi-square for independence tests were employed. Wilcoxon's signed rank test was used for evaluating alterations of the total CT score. The results were expressed as mean ± standard deviation, and a *P*-value less than 0.05 was regarded as statistically significant. Commercially available statistics software was used for data analysis (StatView for Macintosh, Abacus Concepts, Berkeley, CA, USA and Excel for Windows, Microsoft, Redmond, WA, USA).

Results
=======

Clinical profiles and laboratory findings before treatment
----------------------------------------------------------

CyA was added to PSL (PSL + CyA) in 21 patients with DM, including 11 with CADM, and 2 with PM, all of whom showed active IP on or after admission. Possibilities of infection were excluded on the basis of blood examinations, including serum antibodies to infectious agents, and analyses of bronchoalveolar lavage fluid in all of these patients. Twelve DM patients, including 5 with CADM, and 7 with PM were treated only with PSL (PSL alone). Among them 1 DM and 2 PM patients revealed mild consolidation around bronchovascular bundles and/or honey-comb changes on CT, which were regarded as old and inactive IP based on the lack of clinical symptoms with well-preserved respiratory function. Comparison of clinical profiles and laboratory data on admission between PSL alone and PSL + CyA is shown in [Table 1](#t1-cmamd-5-2012-043){ref-type="table"}. There was no significant difference in the initial dose of PSL between PSL alone and PSL + CyA. Among the clinical symptoms of DM, arthralgia and ulcerative skin lesions were significantly more frequent in PSL + CyA (*P* \< 0.0001 and *P* \< 0.001, respectively) than in PSL alone. No significant difference was seen in laboratory data between the 2 groups except for CRP in the DM patients, which showed a significantly higher value in PSL + CyA than in PSL alone (*P* \< 0.01). The total CT score in DM showed a significantly higher level in PSL + CyA than in PSL alone (*P* \< 0.0001).

Therapeutic outcomes
--------------------

Fifteen of the 21 DM patients receiving PSL + CyA (recovery group) showed favorable therapeutic outcomes of IP, including complete recovery, and no serious adverse events except for mild pneumocystis pneumonia in 2. The remaining 6 patients receiving PSL + CyA (death group) died of respiratory failure due to active IP despite methylprednisolone pulse therapy and other intensive immunomodulatory treatment, such as plasma exchange and high-dose intravenous cyclophosphamide. Three of the 6 patients had CADM. The total CT scores of each patient before and after starting coadministration of PSL and CyA are shown in [Figure 1](#f1-cmamd-5-2012-043){ref-type="fig"}. All DM patients in the recovery group showed decreases or at least no increase in the total CT score from 1 month after starting coadministration of PSL and CyA. There were significant decreases in the total CT scores 1, 3, 6 and 12 months after starting coadministration of PSL and CyA compared with before (*P* \< 0.05). All DM patients in the death group showed increases in the total CT score suggestive of worsening of IP even after starting coadministration of PSL and CyA, and died within approximately 3 months after admission. In PM 2 patients received PSL and CyA, and both recovered from active IP without serious adverse events, although the total CT score in 1 remained at a slightly high level owing to inactive interstitial sequellae 12 months after starting this treatment. No patients receiving PSL alone showed any life-threatening complications.

To investigate clinical indices predicting therapeutic outcomes in IP complicating PM/DM, we compared clinical symptoms and laboratory data on adding CyA in the death group with those of the recovery one ([Table 2](#t2-cmamd-5-2012-043){ref-type="table"}). PaO~2~ in room air and %VC were significantly lower in the death group than in the recovery one (*P* \< 0.05). The death group showed lower % DLco compared with the recovery one, but no statistical difference was present. The total CT score was significantly higher in the death group than in the recovery one (*P* \< 0.05). There was no significant difference in clinical symptoms, such as non-productive cough and dyspnea, KL-6, initial dose of PSL or the interval from commencement of PSL to that of CyA between the death and recovery groups. Other treatments, such as methyprednisolone pulse therapy and high-dose intravenous immunoglobulin, were more frequently performed in the death group than in the recovery one in order to avoid worsening of respiratory failure.

Continuous intravenous administration of CyA
--------------------------------------------

Continuous intravenous administration of CyA was performed in 6 DM patients, including 2 with CADM. Clinical profiles and therapeutic outcomes of these patients are summarized in [Table 3](#t3-cmamd-5-2012-043){ref-type="table"}. All of the patients required oxygen therapy on or after admission because of severe dyspnea and non-productive cough with low levels of PaO~2~ in room air, %VC and %DLco, although respiratory function tests could not be performed in some of them. The duration of continuous intravenous administration of CyA was 7 to 15 days (mean 12.5 ± 3.3 days), and the interval between admission to our hospital and commencement of this treatment was 0 to 44 days (mean 9.2 ± 17.3 days). Three patients started to receive continuous intravenous administration of CyA right after admission to our hospital because of rapidly progressive respiratory failure, and of these 2 (patients 5 and 6) completely recovered from IP. After reaching stable general status the administration route of CyA was changed from intravenous to oral in both patients. As a representative case the clinical course of patient 6 is shown in [Figure 2](#f2-cmamd-5-2012-043){ref-type="fig"}. IP quickly improved in parallel with a decrease in serum CK and an increase in SaO~2~ after starting continuous intravenous infusion of CyA and methylprednisolone pulse therapy followed by PSL. The administration route of CyA was successfully changed from intravenous to oral 2 weeks after admission. Nevertheless, the remaining 1 (patient 4), who had already shown consciousness disturbance due to hypoxia on admission, showed improvement of IP only when the blood concentration of CyA was raised to 450 ng/mL or higher. Renal dysfunction ascribable to CyA quickly worsened, and the patient died of respiratory failure during tapering continuous intravenous infusion of this drug.

Discussion
==========

In the present study we reviewed the clinical profiles of PM/DM patients who had received coadministration of CyA and PSL in order to treat associated active IP. All of the patients receiving PSL + CyA, therefore, had active IP, while those receiving PSL alone did not. Considering that the PSL + CyA group showed a significantly higher frequency of ulcerative skin lesions and arthralgia than PSL alone before treatment, DM associated with active IP may have a systemic inflammatory process affecting visceral organs, such as vasculitis, in the background, as shown in the previous report.[@b16-cmamd-5-2012-043] A significantly higher level of CRP in PSL + CyA than in PSL alone also supports the possible presence of systemic vasculitis in DM associated with active IP.

Oral administration of immunosuppressive agents, particularly CyA, is often employed for treatment of acute IP complicating DM in addition to PSL and methylprednisolone pulse therapy.[@b9-cmamd-5-2012-043],[@b17-cmamd-5-2012-043]--[@b19-cmamd-5-2012-043] In the present study 15 DM patients in the recovery group showed quick decreases or at least no increase in the total CT score after starting coadministration of CyA and PSL. Nevertheless, oral CyA has been reported to sometimes fail to sufficiently avoid deterioration of IP, resulting in unfavorable outcomes even if this drug is started from the early phase of illness.[@b20-cmamd-5-2012-043] In the present study 6 DM patients died of respiratory failure due to acute IP despite administration of oral CyA. Among them 4 patients showed an evident delay in commencement of CyA, but in the remaining 2 both PSL and oral CyA were started almost simultaneously right after admission to our hospital in good general status with relatively low values of the total CT score. One possible cause of the unfavorable outcome is that IP was rapidly progressive. In other words, IP may have become irreversible and extensive before CyA extended immunosuppressive action. The other possible cause is that blood concentrations of CyA were not high enough to suppress the disease activity of IP. We raised the administration dose of oral CyA within several days after commencement in these 2 patients in order to keep the trough concentration between 100 and 150 ng/mL, but IP quickly worsened during this period. Oral CyA suppresses autoreactive T cells in conjunction with an increase in blood concentrations after absorption from the gastrointestinal tract. As many exogenous factors, such as food and drugs, can affect the therapeutic efficacy of oral CyA by readily modifying its absorption and metabolism, continuous intravenous administration is often employed for treatment of rejection in organ transplantation[@b21-cmamd-5-2012-043],[@b22-cmamd-5-2012-043] and inflammatory bowel disorders, including ulcerative colitis.[@b23-cmamd-5-2012-043],[@b24-cmamd-5-2012-043] In the present study 6 DM patients with active IP received continuous intravenous administration of CyA because of respiratory failure requiring oxygen therapy with or without mechanical ventilatory support. Four patients showed extensive and probably irreversible damage in both lungs at commencement of the continuous intravenous administration of CyA, finally resulting in death, while the remaining 2 received this treatment from admission to our hospital, and quickly recovered from IP. These results suggest that the continuous intravenous administration of CyA may be a potent therapeutic option in IP complicating DM, particularly in the early phase CyA and PSL in acute IP complicating PM/DM of illness, with regard to its capability of quickly elevating the blood concentration and stabilizing it.

With continuous intravenous administration of CyA both therapeutic effects and adverse events, such as renal dysfunction, depend on its blood concentration. For therapeutic efficacy the appropriate blood concentration with continuous intravenous infusion has been reported to be approximately 2.55-times as high as the trough level with oral administration.[@b22-cmamd-5-2012-043] Considering that the appropriate trough level of CyA in the oral administration is 80--150 ng/mL, therefore, the blood concentration should be kept at approximately 200--380 ng/mL in continuous intravenous infusion. In the present study we controlled the administration speed of CyA in order to keep the blood concentration at 250--350 ng/mL. In the term of safety, adverse events ascribed to CyA have been reported to be dependent on the length of continuous intravenous administration but not on the blood concentration at 300--500 ng/mL.[@b23-cmamd-5-2012-043],[@b25-cmamd-5-2012-043],[@b26-cmamd-5-2012-043] To reduce the possibility of adverse events, therefore, we need to switch the continuous intravenous infusion of CyA to oral administration as soon as possible after reaching stable general status. In the present study 2 patients showed successful transition from continuous intravenous infusion of CyA to oral administration in at most 2 weeks. Renal dysfunction with or without skin eruptions occurred in 2 patients, and of these it rapidly worsened in 1 because the blood concentration of CyA had to be maintained at 450 ng/mL or higher for 10 days in order to treat IP.

According to several recent reports the presence of autoantibodies to CADM-140 in serum and hyperferritinemia are strongly relevant to poor prognosis in IP complicating PM/DM.[@b27-cmamd-5-2012-043],[@b28-cmamd-5-2012-043] At the present time, however, the anti-CADM-140 antibody remains commercially unavailable. To discover other clinical factors suggestive of poor prognosis, we investigated whether or not there was a difference in laboratory data, respiratory function and the total CT score between the death and recovery groups of DM associated with IP. No significant difference was seen in laboratory data, including KL-6, but PaO~2~ and %VC were significantly lower and the total CT score was significantly higher in the death group than in the recovery one. Respiratory function tests showed a lower level also in %DLco in the death group than in the recovery one, although there was no statistical difference. These results suggest that respiratory function, such as PaO~2~, %VC and %DLco, may be useful as clinical indices predicting a poor prognosis. The continuous intravenous administration of CyA is probably adequate for DM patients with active IP who show malfunction in respiratory function tests from the early phase of illness.

In conclusion, coadministration of oral CyA with PSL is effective for IP complicating PM/DM, but its efficacy is sometimes insufficient, particularly in rapidly progressive cases. To more consistently and quickly suppress the disease activity of IP, the continuous intravenous administration of CyA might be a potent therapeutic option. Further prospective study of a larger set of patients is necessary in order to clarify the clinical usefulness of this treatment.
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![The total CT score before and after treatment in the PSL + CyA group.\
**Notes:** The recovery group of the DM patients showed a significant decrease in the total CT score 1, 3, 6 and 12 months after starting PSL and CyA compared with before (*P \<* 0.05), while the death group did not. The total CT score in the PM patients also decreased after starting PSL and CyA.](cmamd-5-2012-043f1){#f1-cmamd-5-2012-043}

![The clinical course of patient 6, showing a decrease in CK and an increase in SaO~2~ during continuous intravenous infusion of CyA and methylprednisolone pulse therapy followed by PSL. The administration route of CyA was successfully changed from intravenous to oral 2 weeks after admission.\
**Abbreviations:** CK, creatine kinase; CT, computed tomography; CyA, cyclosporin A; IV, intravenous; PSL, prednisolone; SaO~2~, arterial oxygen saturation.](cmamd-5-2012-043f2){#f2-cmamd-5-2012-043}

###### 

Comparison of clinical profiles and laboratory data on admission between PSL alone and PSL + CyA.

  Treatment                             Dermatomyositis                                                  Polymyositis                                                            
  ------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------ -------
  Number of patients                    12 (5[\*](#tfn2-cmamd-5-2012-043){ref-type="table-fn"})          21 (11[\*](#tfn2-cmamd-5-2012-043){ref-type="table-fn"})         7      2
  Age of onset (years)                                                                                                                                                           
   Mean                                 61                                                               46                                                               64     66
   SD                                   16                                                               16                                                               17     7
   vs. PSL alone                                                                                         NS                                                                      
  Male/Female                                                                                                                                                                    
   Number                               3/9                                                              10/11                                                            0/7    1/1
   vs. PSL alone                                                                                         NS                                                                      
  Initial dose of PSL (mg/kg/day)                                                                                                                                                
   Mean                                 0.94                                                             1.00                                                             1.00   1.00
   SD                                   0.16                                                             0.28                                                             0      0
   vs. PSL alone                                                                                         NS                                                                      
  Clinical symptoms                                                                                                                                                              
   Muscle weakness                                                                                                                                                               
    Number                              8                                                                10                                                               7      2
    vs. PSL alone                                                                                        NS                                                                      
   Arthralgia                                                                                                                                                                    
    Number                              1                                                                16                                                               0      0
    vs. PSL alone                                                                                        **\<0.0001**                                                            
   Ulcerative skin lesions                                                                                                                                                       
    Number                              0                                                                12                                                               0      0
    vs. PSL alone                                                                                        **0.0008**                                                              
  Laboratory findings                                                                                                                                                            
   WBC (/μL)                                                                                                                                                                     
    Mean                                6235                                                             5228                                                             7363   9830
    SD                                  1993                                                             1251                                                             2397   2772
    vs. PSL alone                                                                                        NS                                                                      
   Lymphocytes (/μL)                                                                                                                                                             
    Mean                                674                                                              796                                                              1666   928
    SD                                  529                                                              453                                                              748    146
    vs. PSL alone                                                                                        NS                                                                      
   CK (IU/L)                                                                                                                                                                     
    Mean                                3261 (6360[\*\*](#tfn3-cmamd-5-2012-043){ref-type="table-fn"})   1825 (3703[\*\*](#tfn3-cmamd-5-2012-043){ref-type="table-fn"})   4348   2558
    SD                                  4616 (4882[\*\*](#tfn3-cmamd-5-2012-043){ref-type="table-fn"})   3513 (4464[\*\*](#tfn3-cmamd-5-2012-043){ref-type="table-fn"})   3124   1190
    vs. PSL alone                                                                                        NS (NS[\*\*](#tfn3-cmamd-5-2012-043){ref-type="table-fn"})              
   CRP (mg/dL)                                                                                                                                                                   
    Mean                                0.25                                                             1.54                                                             0.28   1.83
    SD                                  0.25                                                             2.07                                                             0.26   1.61
    vs. PSL alone                                                                                        **0.006**                                                               
   Positive for anti-nuclear antibody                                                                                                                                            
    Number                              7                                                                3                                                                2      1
    vs. PSL alone                                                                                        NS                                                                      
   Positive for anti-Jo-1 antibody                                                                                                                                               
    Number                              0                                                                1                                                                0      0
    vs. PSL alone                                                                                        NS                                                                      
  Total CT score                                                                                                                                                                 
   Mean                                 0.17                                                             10.75                                                            0.43   10.50
   SD                                   0.58                                                             6.84                                                             0.79   4.95
   vs. PSL alone                                                                                         **\<0.0001**                                                            

**Notes:**

Number of patients with amyopathic dermatomyositis,

Values in patients with non-amyopathic dermatomyositis.

**Abbreviations:** CK, creatine kinase; CRP, C-reactive protein; CyA, cyclosporin A; NS, not significant; PSL, prednisolone; SD, standard deviation; WBC, white blood cells.

###### 

Comparison of clinical profiles and laboratory data on adding CyA between the recovery and death groups of DM patients treated with PSL and CyA.

                                                                Recovery group   Death group
  ------------------------------------------------------------- ---------------- -------------
  Number of patients                                            15               6
  Age (years)                                                                    
   Mean                                                         44               56
   SD                                                           17               10
   vs. recovery group                                                            NS
  Amyopathic type                                                                
   Number                                                       8                3
   vs. recovery group                                                            NS
  Male/Females                                                  7/8              4/2
   Number                                                                        
   vs. recovery group                                                            NS
  Initial dose of PSL (mg/kg/day)                                                
   Mean                                                         0.94             1.08
   SD                                                           0.25             0.20
  vs. recovery group                                                             NS
  Interval between commencement of PSL and that of CyA (days)                    
   Mean                                                         32.0             29.4
   SD                                                           39.3             18.5
   vs. recovery group                                                            NS
  Clinical symptoms                                                              
   Dyspnea                                                                       
    Number                                                      9                5
    vs. recovery group                                                           NS
   Non-productive cough                                                          
    Number                                                      9                6
    vs. recovery group                                                           NS
  Laboratory findings                                                            
   KL-6 (U/L)                                                                    
    Mean                                                        1055             1865
    SD                                                          625              2220
    vs. recovery group                                                           NS
   PaO~2~ in room air (mmHg)                                                     
    Mean                                                        77.8             59.8
    SD                                                          15.0             7.2
    vs. recovery group                                                           **0.017**
   %VC (%)                                                                       
    Mean                                                        86.9             58.3
    SD                                                          13.6             18.7
    vs. recovery group                                                           **0.013**
   %DLco (%)                                                                     
    Mean                                                        57.4             42.1
    SD                                                          9.01             11.9
    vs. recovery group                                                           NS
   Total CT score                                                                
    Mean                                                        8.21             16.7
    SD                                                          5.55.            6.12
    vs. recovery group                                                           **0.013**
  Other treatment                                                                
   Methylprednisolone pulse                                                      
    Number                                                      3                6
   IVIg                                                                          
    Number                                                      0                5
   PE                                                                            
    Number                                                      0                2
   IVCY                                                                          
    Number                                                      0                3

**Abbreviations:** CyA, cyclosporin A; DLco, diffusing capacity for carbon monoxide; DM, dermatomyositis; IVCY, cyclophosphamide pulse; IVIg, high-dose intravenous immunoglobulin; NS, not significant; PE, plasma exchange; PSL, prednisolone; SD, standard deviation; VC, vital capacity.

###### 

Clinical profiles of patients treated with continuous intravenous administration of CyA.

  Patient   Age/Sex   Diagnosis   Clinical symptoms   Respiratory function tests   Total CT score on starting intravenous CyA   Methyl PSL pulse therapy   PSL    CyA   Other treatments   Adverse effects   Therapeutic outcome                                                            
  --------- --------- ----------- ------------------- ---------------------------- -------------------------------------------- -------------------------- ------ ----- ------------------ ----------------- --------------------- --- ---- ---- ------------ ----------------------------- ----------
  1         65/F      DM          \+                  \+                           62.8                                         ND                         ND     19    \+                 \+                7                     0   15   −    PE, IVIg     Renal dysfunction Eruptions   Death
  2         55/F      CADM        \+                  \+                           68.0                                         45.0                       ND     16    \+                 \+                39                    5   14   −    IVCY, IVIg   −                             Death
  3         56/M      CADM        \+                  \+                           61.8                                         43.6                       ND     22    \+                 \+                0                     4   15   −    PE, IVIg     −                             Death
  4         54/F      DM          \+                  \+                           50.8                                         ND                         ND     24    \+                 \+                0                     0   10   −    IVCY, IVIg   Renal dysfunction             Death
  5         52/F      DM          \+                  \+                           60.6                                         45.5                       31.5   16    \+                 \+                0                     0   7    \+   −            −                             Recovery
  6         57/M      DM          \+                  \+                           61.2                                         61.4                       63.6   14    \+                 \+                0                     0   15   \+   −            −                             Recovery

**Abbreviations:** CADM, clinically amyopathic dermatomyositis; CyA, cyclosprin; DLco, diffusing capacity for carbon monoxide; DM, dermatomyositis; IVCY, intravenous cyclophosphamide; IVIg, intravenous high-dose immunoglobulin; ND, not done; PE, plasma exchange; PSL, prednisolone; VC, vital capacity.
